Lisa Astor


Frontline Lenvatinib Shows Superiority to Sorafenib in HCC in Real-World Setting

June 30th 2021

Lenvatinib demonstrated superiority to sorafenib in the first-line setting for patients with unresectable hepatocellular carcinoma, according to results of a propensity score matching analysis.

Naratuximab Emtansine/Rituximab Combo Elicits Clinical Activity in Relapsed/Refractory DLBCL

June 12th 2021

The combination of naratuximab emtansine and rituximab yielded deep responses, and a duration of response that was not reached in patients with relapsed or refractory diffuse large B-cell lymphoma.

Frontline Belzutifan Showcases Significant Clinical Activity in VHL-Associated RCC

June 9th 2021

The hypoxia-inducible factor-2 alpha inhibitor belzutifan maintained clinical efficacy with further follow-up in patients with Von-Hippel Lindau–associated renal cell carcinoma, as well as other VHL-associated neoplasms.

Lifileucel Continues to Demonstrate Durable Responses in Heavily Pretreated Advanced or Metastatic Melanoma

June 6th 2021

Lifileucel has demonstrated promising long-term responses in patients with heavily pretreated advanced or metastatic melanoma who have progressed following PD-1 and PD-L1 inhibition.

Meaningful Impact on Outcomes Demonstrated with De-Escalation Strategy in HER2+/HR– Breast Cancer

June 6th 2021

A de-escalated course of neoadjuvant therapy of trastuzumab and pertuzumab with or without added weekly paclitaxel for only 12 weeks yielded high response rates and significant survival in patients with HER2-positive, hormone receptor–negative early breast cancer.

Amivantamab/Lazertinib Yields Durable Responses in Osimertinib-Relapsed, Chemo-Naïve EGFR+ NSCLC

June 5th 2021

Amivantamab in combination with lazertinib elicited responses in more than one-third of chemotherapy-naïve patients with EGFR-mutant non–small cell lung cancer who had progressed on osimertinib.

Lifileucel Yields Durable Responses in Pretreated Advanced Melanoma

April 11th 2021

The tumor-infiltrating lymphocyte therapy lifileucel was found to elicit durable responses in patients with advanced melanoma who were previously treated with an immune checkpoint inhibitor.

Daratumumab Plus Rd Prolongs PFS in Frail, Newly Diagnosed, Transplant-Ineligible Myeloma

March 18th 2021

The addition of daratumumab to lenalidomide and dexamethasone resulted in improved progression-free survival vs Rd alone in patients with newly diagnosed multiple myeloma who were not eligible for transplant—even in frail patients.

Off-the-Shelf NK Immunotherapy With Chemotherapy and Transplant Shows Early Activity in B-Cell NHL

February 17th 2021

February 17, 2021 — Cord blood–derived natural killer immunotherapy, when paired with high-dose chemotherapy and autologous stem cell transplant, showcased early antitumor activity in patients with B-cell non-Hodgkin lymphoma.

Enfortumab Vedotin Shows Superior Efficacy Over Chemo in Previously Treated Urothelial Carcinoma

February 13th 2021

February 13, 2021 - Enfortumab vedotin was found to have superior efficacy over chemotherapy when used in patients with advanced urothelial carcinoma who had received prior platinum-based chemotherapy and PD-1/L1 inhibition.

Frontline Nivolumab/Cabozantinib Maintains Survival Benefit Over Sunitinib in Advanced RCC

February 13th 2021

February 12, 2021 - The combination of nivolumab and cabozantinib continued to showcase a superior survival benefit over single-agent sunitinib when used as first-line treatment in patients with advanced renal cell carcinoma.

Apamistamab Conditioning Treatment Induces High Rates of HCT Success in AML

February 11th 2021

February 11, 2021 — Apamistamab conditioning treatment with targeted radioimmunotherapy to the bone marrow resulted in high rates of successful allogeneic hematopoietic stem cell transplants in patients with active, relapsed, or refractory acute myeloid leukemia.

Neoadjuvant Atezolizumab Elicits Impressive Responses in Resectable NSCLC

January 30th 2021

January 30, 2021 - Neoadjuvant atezolizumab followed by surgery resulted in a major pathologic response in 21% of patients with resectable stage IB-IIIB non–small cell lung cancer, as well as significant surgical outcomes with a high rate of R0 resection.

COVID-19 Pandemic Has Led to Decrease in Lung Cancer Diagnoses and Increase in Mortality Rate, Study Shows

January 29th 2021

January 29, 2021 - Thirty percent fewer new lung cancer cases have been diagnosed during the coronavirus disease 2019 pandemic versus pre-pandemic, with more symptomatic and severe cases of non–small cell lung cancer diagnosed during this period.

Trastuzumab Deruxtecan Shows Antitumor Activity in HER2-Overexpressing NSCLC

January 29th 2021

January 29, 2021 - The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki demonstrated antitumor activity in patients with HER2-overexpressing non–small cell lung cancer, irrespective of expression levels.

TAS-102 Plus Bevacizumab Improves OS in mCRC Ineligible for Intensive Therapy

January 17th 2021

January 16, 2021 - Trifluridine/tipiracil, when used in combination with bevacizumab, led to an improvement in overall survival over capecitabine/bevacizumab in the frontline treatment of patients with unresectable metastatic colorectal cancer who are not eligible for standard chemotherapy.

Neoadjuvant Chemo Does Not Impact Surgical Risk in Thoracic Esophageal Cancer

January 15th 2021

Neoadjuvant chemotherapy regimens were not found to increase the risk for perioperative complications in patients who have potentially resectable advanced thoracic esophageal cancer.

Sacituzumab Govitecan Improves PFS in Metastatic TNBC With Brain Metastases

December 11th 2020

December 11, 2020 - Sacituzumab govitecan increased response rates and improved progression-free survival vs chemotherapy in patients with metastatic triple-negative breast cancer with stable brain metastases, although no overall survival improvement was observed.

Trilaciclib Before Chemotherapy Significantly Improves OS in Metastatic TNBC

December 10th 2020

The administration of the CDK4/6 inhibitor trilaciclib before chemotherapy comprised of gemcitabine and carboplatin resulted in a significant improvement in overall survival in previously treated patients with metastatic triple-negative breast cancer.

Glofitamab Demonstrates High CR Rate in Relapsed/Refractory NHL

December 7th 2020

December 7, 2020 — The T-cell–engaging bispecific antibody glofitamab elicited a high rate of complete responses, when given in a step-up dosing schedule, in patients with relapsed/refractory non-Hodgkin lymphoma.